Saudi Arabia Pharmaceuticals Market Research Report: Forecast (2025-2030)
Pharmaceuticals Market in Saudi Arabia - By Molecule Type (Conventional Drugs [Small Molecules], Biologics & Biosimilars [Large Molecules]), By Product Type (Branded, Generics), By... Drug Type (Prescription, Over-the-Counter), By Route of Administration (Oral [Tablets, Capsules, Suspensions, Others], Topical, Parenteral [Intravenous, Intramuscular], Inhalation), By Age Group (Adult, Children, Geriatric), By Disease (Cardiovascular Diseases, Cancer, Diabetes, Neurological Disorders, Respiratory Diseases, Autoimmune Diseases, Infectious Diseases, Gastrointestinal Disorders, Mental Health Disorders, Women’s Health Diseases, Dermatological Conditions, Haematological Disorders, Eye Conditions, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North, East, West, Central) Read more
- Healthcare
- Sep 2025
- Pages 111
- Report Format: PDF, Excel, PPT
Saudi Arabia Pharmaceuticals Market
Projected 7.93% CAGR from 2025 to 2030
Study Period
2025-2030
Market Size (2025)
USD 12.37 Billion
Market Size (2030)
USD 18.12 Billion
Base Year
2024
Projected CAGR
7.93%
Leading Segments
By Product Type: Prescription Drugs
Market Insights & Analysis: Saudi Arabia Pharmaceuticals Market (2025-30):
The Saudi Arabia Pharmaceuticals Market size was valued at around USD 12.37 billion in 2025 and is projected to reach USD 18.12 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 7.93% during the forecast period, i.e., 2025-30. The Saudi Arabian Pharmaceuticals Industry is significantly growing due to several growth factors, including the growing efforts by the country’s government through heavy investments by introducing various policies such as the Made in Saudi Arabia Initiative, the Saudi Industrial Development Fund, and many more.
One of the most prominent growth factors is the growing burden of various health problems, such as diabetes, cardiovascular diseases, respiratory disorders, cancer, and infectious diseases, which are increasing the demand for recommended medications and treatments, thus increasing the market size & volume. Additionally, the government is supporting the market by investing heavily in infrastructure development to expand the pharmaceutical industry, including the construction of manufacturing plants, and rising foreign direct investments. These efforts are developing a favorable market environment for the market players to grow & flourish.
Moreover, the research and development have recently gained momentum in Saudi Arabia, backed by the rising investments through public and private partnerships, which have led to the adoption of advanced pharmaceutical products, including biologics and biosimilars in the country, as these are more effective and target specific, providing better treatments, thus uplifting the size & volume of Saudi Arabia Pharmaceuticals Industry.
Saudi Arabia Pharmaceuticals Market Scope:
| Category | Segments |
|---|---|
| By Product Type | Branded, Generics |
| By Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
| By Molecule Type | Conventional Drugs (Small Molecules) , Biologics & Biosimilars (Large Molecules)
|
Furthermore, the widespread presence of retail pharmacies in Saudi Arabia, with the broadest range of products, including drugs, vaccines, dietary supplements, cosmetics, etc., is attracting millions of people and increasing the market growth significantly. However, the country lacks production facilities, due to which it is highly dependent on the imports of pharmaceutical products, thus hindering further market growth.
Saudi Arabia Pharmaceuticals Market Driver:
Increasing Government Support to Expand Manufacturing Units – The market growth is driven by the growing efforts by the Saudi government to expand the local pharmaceutical manufacturing facilities in the country by drafting various policies, such as Vision 2030. For instance, in 2023, Saudi Arabia's sovereign wealth fund launched a contract development and manufacturing organization (CDMO) called Lifera, which aims to focus on the development of essential pharmaceutical products like vaccines, insulins, antibodies, etc. Recently, Saudi Arabia launched its first oncology pharmaceutical plant in Sudair city to increase local production and reduce import dependence. Consequently, more than 55 pharmaceutical factories are approved by the Saudi Food & Drug Authority (SFDA).
Moreover, the Saudi government aims to localize the production of about 70% of the essential medicines in the country by the end of 2030. These kinds of programs are heavily invested in by the government. For instance, in 2024, the national government allocated about USD5 billion in R&D, including drug discovery, thus driving the market growth.
Saudi Arabia Pharmaceuticals Market Challenge:
High Dependence on Imported Products – The market is facing supply chain disruptions as it lacks manufacturing units to produce sufficient pharmaceutical products locally. The country depends on 70%-80% of the pharmaceutical imports to meet the country’s needs. There are fewer than a hundred manufacturing hubs for producing pharmaceutical products in the country, showing the shortage of production capacity. This high dependence on imports has led to a high demand for strong supply chains, which are highly fragmented and create market hindrances.
Additionally, the presence of dispersed local manufacturers in the different parts of the country causes improper connectivity and communication, which ultimately leads to delays in deliveries and affects patient safety. Without a unified platform, the companies are struggling to share the details and are unable to announce the demands effectively, thus restraining the market growth & expansion in the country.
Saudi Arabia Pharmaceuticals Market Trend:
Rapid Adoption of Biologics & Biosimilars – Due to the adoption of advanced pharmaceutical products called biosimilars and biologics in the country, market dynamics are changing positively. These products provide more effective, safer, and targeted therapies with precision and better treatments as compared to other traditional drugs.
Several major companies, such as Daewoong Pharmaceutical, Eisai & Biogen, CEL-SCI Corporation, etc., have launched these products in Saudi Arabia to upgrade the pharmaceutical industry in the country. For instance, in 2025, Eisai & Biogen launched a monoclonal antibody called Lequembi to treat Alzihmer’s disease and recently got approval by SFDA. Similarly, the Multikine immunotherapy injection for head and neck cancer, launched by CEL-SCI Corporation, has recently 2025 received approval from the Saudi regulatory agency. These launches are positively shaping the market growth & expansion in Saudi Arabia.
Saudi Arabia Pharmaceuticals Market (2025-30): Segmentation Analysis
The Saudi Arabia Pharmaceuticals Market study of MarkNtel Advisors evaluates & highlights the major trends and influencing factors in each segment. It includes predictions for the period 2025–2030 at the national level. Based on the analysis, the market has been further classified as:
Based on Product Type:
- Prescription Drugs
- Over-the-counter Drugs
- Biologics & Biosimilar
Among these, the prescription drugs hold the largest market share of about 60%. This segment is dominating due to its high demand because of the rising prevalence of chronic diseases in the country. As per the International Diabetes Federation (IDF) (2024), approximately 5.32 million adults are living with diabetes in the country, while more than 47% of all the deaths caused in Saudi Arabia are due to cardiovascular diseases. These are increasing the demand for prescription drugs in the country, thus contributing to their dominance in this market.
Additionally, the continuously growing elderly population in Saudi Arabia is accelerating the prescription drugs segment, as this population is highly prone to these diseases, which increases the demand for these drugs. For instance, as of 2024, about 1 million people are aged 65 years old, which is expected to rise sharply and is contributing to the high demand for prescription drugs in the country.
Based on Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Out of these, the hospital pharmacies are the most preferred distribution channel in this market, accounting for more than 42% of the market share. The factor contributing to the market’s growth is the large volume of patient visits to hospitals for regular check-ups, so they prefer to take medications from the corresponding hospital pharmacies. Additionally, the customers’ trust related to pharmacies in hospitals is contributing to the market’s growth. Therefore, there are about 498 hospitals in Saudi Arabia, and 95% of these have their own pharmacies, showing their dominance in the market.
Also, hospital pharmacies are integrated with healthcare services such as diagnostics and treatment, making them convenient for patients to get prescribed medicines quickly, improving treatment adherence. This is due to some of the medications being prescription drugs only, that is only written in hospitals during checkups, so it makes it easier for the patients to purchase the drugs from the nearest distribution channel, that is, the hospital pharmacies, thus these distribution channels are generating maximum market revenue.
Saudi Arabia Pharmaceuticals Industry Recent Development:
- 2025: Sanofi is transferring its insulin manufacturing expertise to Saudi Arabia by partnering with Sudair Pharma Company (SPC) and NUPCO. The new facility will locally produce and package advanced SoloStar insulin pens, with a capacity of ~15 million pens annually, serving about 500,000 patients and covering approximately 70% of insulin users in the Kingdom.
- 2024: Tabuk Pharmaceuticals partnered with Biocon to commercialize GLP-1 treatments for diabetes in the Middle East, marking a strategic expansion into specialty medicines.
Gain a Competitive Edge with Our Saudi Arabia Pharmaceuticals Market Report
- Saudi Arabia Pharmaceuticals Market Report by MarkNtel Advisors provides a detailed & thorough analysis of market size & share, growth rate, competitive landscape, and key players. This comprehensive analysis helps businesses gain a holistic understanding of the market dynamics & make informed decisions.
- This report also highlights current market trends & future projections, allowing businesses to identify emerging opportunities & potential challenges. By understanding market forecasts, companies can align their strategies & stay ahead of the competition.
- Saudi Arabia Pharmaceuticals Market Report aids in assessing & mitigating risks associated with entering or operating in the market. By understanding market dynamics, regulatory frameworks, and potential challenges, businesses can develop strategies to minimize risks & optimize their operations.
*Reports Delivery Format - Market research studies from MarkNtel Advisors are offered in PDF, Excel and PowerPoint formats. Within 24 hours of the payment being successfully received, the report will be sent to your email address.
Frequently Asked Questions
- Market Segmentation
- Introduction
- Product Definition
- Research Process
- Assumptions
- Executive Summary
- Saudi Arabia Pharmaceuticals Market Regulations, Policies & Standards
- Drug Registration & Approval Process (SFDA, etc.)
- Import/Export Regulations
- Patent Laws & IP Protection
- Pharmacovigilance & Compliance
- Recent Policy Changes (e.g. local manufacturing push)
- Saudi Arabia Healthcare Overview
- Economic Snapshot & Demographics
- Healthcare System Structure (Public vs. Private)
- Government Vision & Health Initiatives (e.g., Vision 2030)
- Saudi Arabia Pharmaceutical Local Manufacturing & Industrialization Push
- Saudi Arabia Pharma Manufacturing Landscape
- Incentives for Local Production
- Technology/Knowledge Transfer & R&D Capabilities
- Others
- Saudi Arabia Pharmaceuticals Market Trends & Developments
- Saudi Arabia Pharmaceuticals Market Dynamics
- Growth Drivers
- Challenges
- Saudi Arabia Pharmaceuticals Market Hotspots & Opportunities
- Saudi Arabia Pharmaceuticals Market Value Chain Analysis
- Saudi Arabia Pharmaceuticals Market Outlook, 2020- 2030F
- Market Size & Analysis
- Market Revenues (USD Million)
- Market Share & Analysis
- By Molecule Type
- Conventional Drugs (Small Molecules)- Market Size & Forecast 2020-2030, USD Million
- Biologics & Biosimilar (Large Molecules)- Market Size & Forecast
- By Product Type
- Branded- Market Size & Forecast 2020-2030, USD Million
- Generics- Market Size & Forecast 2020-2030, USD Million
- By Drug Type
- Prescription- Market Size & Forecast 2020-2030, USD Million
- Over the Counter- Market Size & Forecast 2020-2030, USD Million
- By Route of Administration
- Oral- Market Size & Forecast 2020-2030, USD Million
- Tablets- Market Size & Forecast 2020-2030, USD Million
- Capsules- Market Size & Forecast 2020-2030, USD Million
- Suspensions- Market Size & Forecast 2020-2030, USD Million
- Others- Market Size & Forecast 2020-2030, USD Million
- Topical- Market Size & Forecast 2020-2030, USD Million
- Parenteral- Market Size & Forecast 2020-2030, USD Million
- Intravenous- Market Size & Forecast 2020-2030, USD Million
- Intramuscular- Market Size & Forecast 2020-2030, USD Million
- Inhalation- Market Size & Forecast 2020-2030, USD Million
- Oral- Market Size & Forecast 2020-2030, USD Million
- By Age Group
- Adult- Market Size & Forecast 2020-2030, USD Million
- Children- Market Size & Forecast 2020-2030, USD Million
- Geriatric- Market Size & Forecast 2020-2030, USD Million
- By Disease
- Cardiovascular Diseases- Market Size & Forecast 2020-2030, USD Million
- Cancer- Market Size & Forecast 2020-2030, USD Million
- Diabetes- Market Size & Forecast 2020-2030, USD Million
- Neurological Disorders- Market Size & Forecast 2020-2030, USD Million
- Respiratory Diseases- Market Size & Forecast 2020-2030, USD Million
- Autoimmune Diseases- Market Size & Forecast 2020-2030, USD Million
- Infectious Diseases- Market Size & Forecast 2020-2030, USD Million
- Gastrointestinal Disorders- Market Size & Forecast 2020-2030, USD Million
- Mental Health Disorders- Market Size & Forecast 2020-2030, USD Million
- Women’s Health Diseases- Market Size & Forecast 2020-2030, USD Million
- Dermatological Conditions- Market Size & Forecast 2020-2030, USD Million
- Haematological Disorders- Market Size & Forecast 2020-2030, USD Million
- Eye Conditions- Market Size & Forecast 2020-2030, USD Million
- Others- Market Size & Forecast 2020-2030, USD Million
- By Distribution Channel
- Hospital Pharmacies- Market Size & Forecast 2020-2030, USD Million
- Retail Pharmacies- Market Size & Forecast 2020-2030, USD Million
- Online Pharmacies- Market Size & Forecast 2020-2030, USD Million
- By Region
- North
- East
- West
- Central
- By Competitors
- Competition Characteristics
- Market Share & Analysis
- By Molecule Type
- Market Size & Analysis
- Saudi Arabia Conventional Drugs (Small Molecules) Market Outlook, 2020- 2030F
- Market Size & Analysis
- Market Revenues (USD Million)
- Market Share & Analysis
- By Product Type- Market Size & Forecast 2020-2030, USD Million
- Analgesics & Anti Inflammatory
- Antipyretic
- Antibiotics
- Antivirals
- Antidepressants
- Others
- By Drug Type- Market Size & Forecast 2020-2030, USD Million
- By Route of Administration- Market Size & Forecast 2020-2030, USD Million
- By Age Group- Market Size & Forecast 2020-2030, USD Million
- By Disease- Market Size & Forecast 2020-2030, USD Million
- By Distribution Channel- Market Size & Forecast 2020-2030, USD Million
- By End User- Market Size & Forecast 2020-2030, USD Million
- By Product Type- Market Size & Forecast 2020-2030, USD Million
- Market Size & Analysis
- Saudi Arabia Biologics & Biosimilar (Large Molecules) Market Outlook, 2020- 2030F
- Market Size & Analysis
- Market Revenues (USD Million)
- Market Share & Analysis
- By Type - Market Size & Forecast 2020-2030, USD Million
- Monoclonal Antibodies- Market Size & Forecast 2020-2030, USD Million
- Growth Factors- Market Size & Forecast 2020-2030, USD Million
- Insulin- Market Size & Forecast 2020-2030, USD Million
- Vaccines- Market Size & Forecast 2020-2030, USD Million
- Therapeutic Enzymes- Market Size & Forecast 2020-2030, USD Million
- Colony Stimulation Factors- Market Size & Forecast 2020-2030, USD Million
- Interferons- Market Size & Forecast 2020-2030, USD Million
- Fusion Protein- Market Size & Forecast 2020-2030, USD Million
- Immunomodulators- Market Size & Forecast 2020-2030, USD Million
- Erythoprotein- Market Size & Forecast 2020-2030, USD Million
- Orthobiologics- Market Size & Forecast 2020-2030, USD Million
- Platelet-Rich Plasma (PRP)- Market Size & Forecast 2020-2030, USD Million
- Stem Cell Therapies- Market Size & Forecast 2020-2030, USD Million
- Hyaluronic Acid Injections- Market Size & Forecast 2020-2030, USD Million
- Growth Factors/Bone Morphogenetic Proteins (BMPs)- Market Size & Forecast 2020-2030, USD Million
- By Type - Market Size & Forecast 2020-2030, USD Million
- By Product Type- Market Size & Forecast 2020-2030, USD Million
- By Drug Type- Market Size & Forecast 2020-2030, USD Million
- By Route of Administration- Market Size & Forecast 2020-2030, USD Million
- By Age Group- Market Size & Forecast 2020-2030, USD Million
- By Disease- Market Size & Forecast 2020-2030, USD Million
- By Distribution Channel- Market Size & Forecast 2020-2030, USD Million
- By End User- Market Size & Forecast 2020-2030, USD Million
- Market Size & Analysis
- Saudi Arabia Pharmaceuticals Market Key Strategic Imperatives for Growth & Success
- Competitive Outlook
- Company Profiles
- Pfizer
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Sanofi
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Novartis
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- SPIMACO
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Tabuk Pharmaceuticals
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Jamjoom Pharma
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Riyadh Pharma
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- GlaxoSmithKline
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Hikma Pharmaceuticals
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- AstraZeneca
- Business Description
- Product Portfolio
- Strategic Alliances or Partnerships
- Recent Developments
- Financial Details
- Others
- Others
- Pfizer
- Company Profiles
- Disclaimer
MarkNtel Advisors follows a robust and iterative research methodology designed to ensure maximum accuracy and minimize deviation in market estimates and forecasts. Our approach combines both bottom-up and top-down techniques to effectively segment and quantify various aspects of the market. A consistent feature across all our research reports is data triangulation, which examines the market from three distinct perspectives to validate findings. Key components of our research process include:
1. Scope & Research Design At the outset, MarkNtel Advisors define the research objectives and formulate pertinent questions. This phase involves determining the type of research—qualitative or quantitative—and designing a methodology that outlines data collection methods, target demographics, and analytical tools. They also establish timelines and budgets to ensure the research aligns with client goals.
2. Sample Selection and Data Collection In this stage, the firm identifies the target audience and determines the appropriate sample size to ensure representativeness. They employ various sampling methods, such as random or stratified sampling, based on the research objectives. Data collection is carried out using tools like surveys, interviews, and observations, ensuring the gathered data is reliable and relevant.
3. Data Analysis and Validation Once data is collected, MarkNtel Advisors undertake a rigorous analysis process. This includes cleaning the data to remove inconsistencies, employing statistical software for quantitative analysis, and thematic analysis for qualitative data. Validation steps are taken to ensure the accuracy and reliability of the findings, minimizing biases and errors.
4. Data Forecast and FinalizationThe final phase involves forecasting future market trends based on the analyzed data. MarkNtel Advisors utilize predictive modeling and time series analysis to anticipate market behaviors. The insights are then compiled into comprehensive reports, featuring visual aids like charts and graphs, and include strategic recommendations to inform client decision-making
We offer flexible licensing options to cater to varying organizational needs. Choose the pricing pack that best suits your requirements:
Buy Now
Inquire Before Buying
Talk to our Consultant
Request Customization
Global / Regional Reports 
